Earnings Summary

Cue Biopharma Inc’s revenue jumped 5215.38% since last year same period to $1.38Mn in the Q2 2023. On a quarterly growth basis, Cue Biopharma Inc has generated 639.04% jump in its revenue since last 3-months.

Cue Biopharma Inc’s net profit jumped 0.17% since last year same period to $-13.19Mn in the Q2 2023. On a quarterly growth basis, Cue Biopharma Inc has generated -0.58% fall in its net profits since last 3-months.

Cue Biopharma Inc’s net profit margin jumped 98.12% since last year same period to -954.05% in the Q2 2023. On a quarterly growth basis, Cue Biopharma Inc has generated 86.39% jump in its net profit margins since last 3-months.

Cue Biopharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.34 - a 10.53% jump from last quarter’s estimates.

Cue Biopharma Inc’s earning per share (EPS) estimates for the current year stand at -0.34.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Cue Biopharma Inc’s return on assets (ROA) stands at -0.42.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Cue Biopharma Inc’s return on equity (ROE) stands at -0.98.